Journal article
Does Pretreatment Seropositivity to Human Papillomavirus Have Prognostic Significance for Head and Neck Cancers?
Cancer epidemiology, biomarkers & prevention, Vol.17(8), pp.2087-2096
2008
DOI: 10.1158/1055-9965.EPI-08-0054
PMCID: PMC4443901
PMID: 18708401
Abstract
Background: Human papillomavirus (HPV) is a risk factor for head and neck cancers (HNC), yet HPV-associated tumors have better prognosis than HPV-negative tumors.
Methods: We evaluated whether pretreatment presence of antibodies to HPV capsids [virus-like particles (VLP)] or to HPV-16 oncoproteins E6 and E7 was a predictor of HPV-positive HNC and clinical outcomes. Sera from 156 HNC patients were tested for antibodies to HPV-16–derived antigens using ELISA. HPV-16 in tumors was evaluated by PCR and DNA sequencing.
Results: HPV-16 antibodies were found in 33% with HPV-16 VLP, 21% with HPV-16 E6, and 21% with E7. HPV-16 was detected in 26% of tumors. There was a strong correlation between detection of HPV-16 tumor DNA and antibodies to HPV-16 E6 or E7 (κ = 0.7) but not to HPV-16 VLP (κ = 0.4). Multivariate analyses showed significantly better disease-specific survival in seropositive HPV-16 VLP [hazard ratio (HR), 0.4; 95% confidence interval (95% CI), 0.1-0.9], HPV-16 E6 (HR, 0.1; 95% CI, 0.02-0.5), and HPV-16 E7 (HR, 0.3; 95% CI, 0.1-0.9) cases. Less disease recurrence occurred among those with antibodies to both E6 and E7 compared with those negative to both (P = 0.003). There was better disease-specific survival in patients who were E6 positive at baseline and remained positive at follow-up compared with individuals who were E6 negative at both time points (P = 0.03; κ = 0.9).
Conclusions: The presence of antibodies to HPV-16 E6 and E7 is associated with HPV in tumor cells and with better clinical outcomes. These findings suggest that the presence of E6/E7 antibodies before treatment is predictive of better clinical outcomes and that they may serve as biomarkers for selecting targeted therapeutic modalities developed for HPV-associated tumors. (Cancer Epidemiol Biomarkers Prev 2008;17(8):2087–96)
Details
- Title: Subtitle
- Does Pretreatment Seropositivity to Human Papillomavirus Have Prognostic Significance for Head and Neck Cancers?
- Creators
- Elaine M SMITH - Department of Epidemiology, University of Iowa, United StatesLinda M RUBENSTEIN - Department of Epidemiology, University of Iowa, United StatesJustine M RITCHIE - Department of Biostatistics, College of Public Health, University of Iowa, United StatesJohn H LEE - Department of Otolaryngology, University of Iowa, United StatesThomas H HAUGEN - Department of Pathology, College of Medicine, University of Iowa, United StatesEva HAMSIKOVA - Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech RepublicLubomir P TUREK - Department of Pathology, College of Medicine, University of Iowa, United States
- Resource Type
- Journal article
- Publication Details
- Cancer epidemiology, biomarkers & prevention, Vol.17(8), pp.2087-2096
- Publisher
- American Association for Cancer Research; Philadelphia, PA
- DOI
- 10.1158/1055-9965.EPI-08-0054
- PMID
- 18708401
- PMCID
- PMC4443901
- ISSN
- 1055-9965
- eISSN
- 1538-7755
- Language
- English
- Date published
- 2008
- Academic Unit
- Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9984047686902771
Metrics
24 Record Views